Rafferty Asset Management, LLC Cytokinetics Inc Transaction History
Rafferty Asset Management, LLC
- $29.4 Billion
- Q2 2025
A detailed history of Rafferty Asset Management, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 171,581 shares of CYTK stock, worth $10.2 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
171,581
Previous 149,507
14.76%
Holding current value
$10.2 Million
Previous $6.01 Million
5.64%
% of portfolio
0.02%
Previous 0.03%
Shares
26 transactions
Others Institutions Holding CYTK
# of Institutions
383Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.04 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$871 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$711 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$465 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$378 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.59B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...